Products from BPS Bioscience require a minimum order value above 400€
Encompassing Amino Acids: 2-1226(end)
Application: Useful for the study of binding of ADAR1 and RNA and screening inhibitors of this interaction.
Background: ADAR1 (adenosine deaminase, RNA-specific 1) performs adenosine to inosine base
editing in RNA, particularly targeting adenosines located within a specific stem-loop
motif structure. It is proposed that ADARs evolved to provide additional diversity to the
transcriptome and while the majority of ADAR editing events occur in non-coding RNAs, some, including the canonical GluA2 editing site, alter the amino acid sequence of coding proteins. ADAR1 plays a role in innate immunity by mitigating interferon
signaling. Dysfunction of ADAR1 results in autoimmune disorders, and impacts cancer
cell growth and proliferation as well as tumor response to immunotherapy. Since ADAR
recognizes double-stranded RNA, it also functions to suppress or modify RNA viruses.
Thus, it is implicated in viral evolution and in the emergence of viral variants such as
SARS-CoV-2 variants. The E1008Q mutant of ADAR1 has been proposed to demonstrate higher editing activity than its wild type, with the mutation being present in an highly conserved glutamate present in the deaminase domain of the protein.
Concentration: 0.39 mg/ml
Description: Recombinant human full-length ADAR1 (adenosine deaminase, RNA-specific 1) transcript 1, encompassing amino acids 2-1226(end). This protein contains the mutation of interest E1008Q. This construct contains an N-terminal FLAG-tag. The recombinant protein was affinity purified.
Format: Aqueous buffer solution
Formulation: 50 mM Tris-HCl, pH 8.0, 750 mM NaCl, 0.01% Triton X-100, 10% glycerol and 100 µg/ml FLAG peptide.
Genbank: NM_001111
Purity: ≥80%
Storage Stability: >6 months at –80°C.
Uniprot: P55265
Warnings: Avoid freeze/thaw cycles. Protein may be diluted to ≥ 100 µg/ml in PBS + glycerol and stored at -80°C.
Biosafety Level: Not applicable (BSL-1)
English
Deutsch
